First-line single-agent cetuximab in patients with advanced colorectal cancer
Open Access
- 10 December 2007
- journal article
- research article
- Published by Elsevier in Annals of Oncology
- Vol. 19 (4) , 711-716
Abstract
Background: The anti-epidermal growth factor receptor (EGFR) antibody cetuximab is active in heavily pretreated patients with metastatic colorectal cancer (mCRC) both in monotherapy and in combination with chemotherapy (CT). This study assesses the antitumor activity of single-agent cetuximab in CT-naive patients. Patients and methods: Phase II clinical trial was used. Patients were EGFR positive by immunohistochemistry and were not candidate for radical surgery, even in the case of substantial tumor shrinkage. Cetuximab was administered weekly. Results: Thirty-nine patients were treated and evaluated. The most common adverse event was skin toxicity (89% any grade; 48% grade 1; 31% grade 2; 10% grade 3). One patient had a complete response and three obtained partial responses (10% overall response rate). Thirteen patients had stable disease (34%). Twenty-two patients experienced progressive disease (56%). Overall median time to progression (TTP) was 2 months, and the responders individual TTP was 12, 9, 9, and 6 months. Conclusions: Even in chemo-naive patients, cetuximab as single agent is active only in a small fraction of mCRC, similarly to what has been reported for heavily pretreated patients. The extent of benefit when response occurs is, however, such that it is mandatory to intensify the search for the predictive markers of response to cetuximab therapy.Keywords
This publication has 26 references indexed in Scilit:
- Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trialThe Lancet, 2007
- A meta-analysis of two randomised trials of early chemotherapy in asymptomatic metastatic colorectal cancerBritish Journal of Cancer, 2005
- Systemic Therapy for Metastatic Colorectal Cancer: Current Options, Current EvidenceJournal of Clinical Oncology, 2005
- Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal CancerNew England Journal of Medicine, 2004
- Survival of Patients With Advanced Colorectal Cancer Improves With the Availability of Fluorouracil-Leucovorin, Irinotecan, and Oxaliplatin in the Course of TreatmentJournal of Clinical Oncology, 2004
- FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR StudyJournal of Clinical Oncology, 2004
- Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicentre randomised trialThe Lancet, 2003
- Resection rate and effect of postoperative chemotherapy on survival after surgery for colorectal liver metastasesBritish Journal of Surgery, 2001
- Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study.Journal of Clinical Oncology, 1997
- Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: a randomized trial.Journal of Clinical Oncology, 1992